SCHEMBL2460338

SCHEMBL2460338

O=c1nc(NCc2ccco2)cc[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.55
▸ MEN1 O00255 4/20 0.55
▸ HSD17B10 Q99714 3/20 0.55
▸ PKM P14618 1/20 0.55
▸ DNMT1 P26358 1/20 0.48
▸ SMN1; SMN2 Q16637 5/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ MAPK1 P28482 3/20 0.48
▸ LMNA P02545 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ HTT P42858 2/20 0.48
▸ BLM P54132 1/20 0.48
▸ PNP P00491 1/20 0.47
▸ KCNH3 Q9ULD8 2/20 0.47
▸ TP53 P04637 3/20 0.46
▸ HPGD P15428 3/20 0.46
▸ TSHR P16473 2/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14244140 0.74 ALDH1A1 (0.34) KMT2AMEN1HSD17B10PKMTSHR
SCHEMBL2467960 0.74 KMT2A (0.67) KMT2AMEN1HSD17B10PKMSMN1; SMN2
SCHEMBL248683 0.73 ELANE (0.50) KMT2AMEN1HSD17B10KDM4ELMNA
SCHEMBL16248323 0.72 SMN1; SMN2 (0.54) KMT2AMEN1HSD17B10SMN1; SMN2KDM4E
SCHEMBL27884100 0.72 KDM4E (0.50) KMT2AMEN1HSD17B10SMN1; SMN2KDM4E
SCHEMBL18133228 0.72 KMT2A (0.42) KMT2AMEN1HSD17B10PKMDNMT1
SCHEMBL2463433 0.72 KMT2A (0.57) KMT2AMEN1HSD17B10PKMDNMT1
SCHEMBL236001 0.71 ALDH1A1 (0.33) ALDH1A1POLB
SCHEMBL19692262 0.71 ALDH1A1 (0.33) ALDH1A1POLB
SCHEMBL65489 0.71 CACNA1C (0.42) ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2225228-B1 METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION INST CHEMII BIOORG PAN (PL) 2016-10-12 — — EP claimed
US-8404660-B2 Method of obtaining of 4-N-furfurylcytosine and/or its derivatives, an anti-aging composition and use of 4-N-furfurylcytosine and/or its derivatives in the manufacture of anti-aging composition INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2013-03-26 — — US claimed
US-20100317612-A1 METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2010-12-16 — — US claimed
EP-2225228-A2 METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION Instytut Chemii Bioorganicznej PAN (PL) 2010-09-08 — — EP claimed
WO-2009067035-A2 METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2009-05-28 — — WO claimed
EP-2556081-B1 A CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION INST CHEMII BIOORGANICZNEJ PAN (PL) 2021-06-16 — — EP disclosed
EP-2556081-B1 A CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION INST CHEMII BIOORGANICZNEJ PAN (PL) 2021-06-16 — — EP disclosed
EP-2225228-B1 METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION INST CHEMII BIOORG PAN (PL) 2016-10-12 — — EP disclosed
US-9040490-B2 Cytosine analogue, a method of preparation of a cytosine analogue, a DNA methyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2015-05-26 — — US disclosed
US-9040490-B2 Cytosine analogue, a method of preparation of a cytosine analogue, a DNA methyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2015-05-26 — — US disclosed
US-9040490-B2 Cytosine analogue, a method of preparation of a cytosine analogue, a DNA methyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2015-05-26 — — US disclosed
US-8404660-B2 Method of obtaining of 4-N-furfurylcytosine and/or its derivatives, an anti-aging composition and use of 4-N-furfurylcytosine and/or its derivatives in the manufacture of anti-aging composition INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2013-03-26 — — US disclosed
US-20120322755-A1 CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2012-12-20 — — US disclosed
US-20120322755-A1 CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2012-12-20 — — US disclosed
US-20120322755-A1 CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2012-12-20 — — US disclosed
WO-2011115513-A2 A CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2011-09-22 — — WO disclosed
US-20100317612-A1 METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2010-12-16 — — US disclosed
US-20100317612-A1 METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2010-12-16 — — US disclosed
EP-2225228-A2 METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION Instytut Chemii Bioorganicznej PAN (PL) 2010-09-08 — — EP disclosed
WO-2009067035-A2 METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2009-05-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317612-A1 METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION GLA, GALE, RNGTT KMT2A 1851/4885MEN1 4097/4885HSD17B10 2364/4885
US-20120322755-A1 CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION DNMT1, DIMT1, TPMT KMT2A 111/4885MEN1 715/4885HSD17B10 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback